ELAVL1 and ovarian cancer: Ovarian cancer (OV) exhibited HuR-mediated platinum/taxane sensitization (Cisplatin, Paclitaxel; R = 0.48-0.55, p < 0.01) contrasted with PARP inhibitor resistance in BRCA-mutant contexts (R = -0.45, p < 0.01).